Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNM1 | Q05193 | 2/20 | 0.50 |
| ▸ | FAAH | O00519 | 4/20 | 0.43 |
| ▸ | LPAR1 | Q92633 | 2/20 | 0.41 |
| ▸ | LPAR2 | Q9HBW0 | 2/20 | 0.41 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.41 |
| ▸ | GLP1R | P43220 | 8/20 | 0.40 |
| ▸ | CNR1 | P21554 | 1/20 | 0.40 |
| ▸ | CNR2 | P34972 | 1/20 | 0.40 |
| ▸ | CASP2 | P42575 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26032010 | 0.94 | DNM1 (0.46) | DNM1FAAHLPAR1LPAR2ENPP2 | |
| SCHEMBL26032011 | 0.94 | DNM1 (0.46) | DNM1FAAHLPAR1LPAR2ENPP2 | |
| SCHEMBL26032016 | 0.92 | DNM1 (0.40) | DNM1FAAHGLP1RCASP2 | |
| SCHEMBL23567384 | 0.82 | FAAH (0.51) | DNM1FAAHLPAR1LPAR2ENPP2 | |
| SCHEMBL25067300 | 0.80 | FAAH (0.59) | DNM1FAAHLPAR1LPAR2ENPP2 | |
| SCHEMBL21787000 | 0.80 | FAAH (0.49) | DNM1FAAHLPAR1LPAR2ENPP2 | |
| SCHEMBL20856919 | 0.79 | FAAH (0.65) | DNM1FAAHLPAR1LPAR2ENPP2 | |
| SCHEMBL28999762 | 0.79 | FAAH (0.65) | DNM1FAAHLPAR1LPAR2ENPP2 | |
| SCHEMBL31683866 | 0.79 | FAAH (0.65) | DNM1FAAHLPAR1LPAR2ENPP2 | |
| SCHEMBL16028184 | 0.77 | DNM1 (0.70) | DNM1FAAHLPAR1CNR1CASP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230265429-A1 | SKELETAL MUSCLE DELIVERY PLATFORMS AND METHODS OF USE THEREOF | Arrowhead Pharmaceuticals, Inc. | 2023-08-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230265429-A1 | SKELETAL MUSCLE DELIVERY PLATFORMS AND METHODS OF USE THEREOF | MUSK, MYLK2, TNNC1 | DNM1 695/4885FAAH 4742/4885LPAR1 1841/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.